Science technology concept. Research and Development. Drug discovery.

metamorworks

The following segment was excerpted from this fund letter.


Calumet Specialty Products Partners (NASDAQ:CLMT)

We recently initiated an investment in Calumet in the event-driven portfolio. Calumet fits firmly within the “moderate risk, high reward” bucket of our portfolio for reasons that will be

Source link